Search the Newsreel

Kenvue Inc. (KVUE) Stock Forecasts

Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, having spun off from Johnson & Johnson in May 2023. Recent earnings show rare volume growth despite muted performance in the US and Europe. Analysts continue to evaluate its market position and financial …

Kenvue (NYSE:KVUE) Posts Earnings Results, Misses Expectations By $0.01 EPS

Kenvue (NYSE:KVUE) reported its quarterly earnings, missing analyst expectations by $0.01 EPS with $0.31 per share, against an estimated $0.32. The company's revenue of $3.96 billion also slightly missed the $3.97 billion forecast but marked a 3.0% increase year-over-year. Kenvue declared a quarterly dividend …

Press Release: Kenvue Reports Second Quarter 2026 Results

This document is a press release from Kenvue reporting their second quarter 2026 financial results. Without further content, the specific details of these results are unknown.

Kenvue Inc. stock falls Thursday, underperforms market

Kenvue Inc. (KVUE) stock fell by 2.49% on Thursday, closing at $19.18, and underperformed the broader market. This decline occurred during an overall poor trading session where the S&P 500 Index dropped 0.18% and the Dow Jones Industrial Average fell 0.85%. The stock's fall …

Kenvue Stock Falls 2.7% as Growth Arrives With Thinner Margins

This article first appeared on GuruFocus. Kenvue (NYSE:KVUE), the consumer-health giant behind Tylenol, Neutrogena and Listerine, delivered another quarter of steady growth, but that was not enough to keep investors happy as the stock slid about 2.7% on Thursday. Revenue climbed 3% year over …

KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise

Kenvue Inc. (KVUE) reported its Q2 2026 results, with both adjusted earnings and net sales missing Zacks Consensus Estimates despite showing increases year-over-year. The company experienced narrowing margins due to inflation and foreign exchange, while its Self Care segment returned to organic growth and …

Kenvue second quarter results fall short of expectations, sending shares lower

Kenvue Inc. (NYSE:KVUE) reported second-quarter results that fell slightly below Wall Street expectations, causing its shares to drop by about 2%. The consumer health company reported adjusted diluted earnings per share of $0.31 on revenue of $3.96 billion, missing analyst estimates of $0.32 EPS …

Market movers: Western Digital, Sandisk, Kenvue, Fiserv...

Fiserv, Kenvue, Western Digital, and Sandisk experienced declines due to lowered outlooks or missed expectations. Fiserv's shares fell over 3% after reducing its 2026 organic revenue forecast, while Kenvue's shares dropped 2% after missing Q2 earnings estimates. Western Digital and Sandisk both saw their …

FMR LLC discloses 8.2% Kenvue Inc. (KVUE) ownership in amended 13G filing

FMR LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 8.2% in Kenvue Inc. (KVUE), amounting to 157,051,418.71 shares of common stock. The filing details FMR LLC's sole voting power over 107,583,737.47 shares and sole dispositive power over the full 157,051,418.71 …

Kenvue stock falls after earnings miss analyst estimates

Kenvue Inc. shares dropped in premarket trading after the company reported second-quarter results that missed Wall Street's earnings and revenue estimates. Despite the miss, Kenvue saw its third consecutive quarter of net and organic sales growth, with gains across all segments and regions, and …

Kenvue misses quarterly estimates as inflation, tariffs squeeze margins

Aug 6 (Reuters) - Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, ‌tariffs and currency-related costs squeezed margins. The consumer-health ‌company, currently in the midst of a $40 billion buyout by Kimberly-Clark, ​expects the deal to close in the …

Kenvue incumple las previsiones trimestrales por la presión de la inflación y los aranceles sobre sus márgenes

Kenvue Posts Higher Profit, Sales as Turnaround Continues

Kenvue reported higher profit and sales in the second quarter, with net sales increasing 3% to $3.96 billion, slightly below Wall Street estimates. The company, known for products like Tylenol and Listerine, achieved a profit of $456 million, or 24 cents a share, up …

Earnings Flash (KVUE) Kenvue Inc. Posts Q2 Adjusted EPS $0.31 per Share, vs. FactSet Est of $0.32

Kenvue Inc. (KVUE) reported its Q2 adjusted earnings per share (EPS) of $0.31, which fell short of FactSet's estimate of $0.32. This financial update indicates that the company's Q2 performance did not meet analyst expectations for its adjusted EPS. The article is part of …

Kenvue Inc. 1Q 2026: Revenue $3.96B, EPS $0.24— 10-Q Summary

Kenvue Inc. reported strong first-quarter 2026 results, with revenue of $3.96 billion and diluted EPS of $0.24, exceeding prior-year figures. Growth was primarily driven by e-commerce strength and significant gains in its Skin Health & Beauty segment. The company also highlighted ongoing operational initiatives, …

Earnings Flash (KVUE) Kenvue Inc. Reports Q2 Revenue $3.96B, vs. FactSet Est of $3.97B

Kenvue Inc. (KVUE) reported its Q2 revenue at $3.96 billion, falling slightly short of FactSet's estimate of $3.97 billion. This announcement follows earlier news that Kenvue missed quarterly estimates due to inflation and tariffs squeezing margins, and also reported Q2 adjusted EPS of $0.31 …

Kenvue Inc. (KVUE) Q2 2026 Earnings

Kenvue Inc. (KVUE) reported its Q2 2026 earnings, missing analyst expectations for both EPS ($0.31 vs $0.32 est) and revenue ($3.96B vs $3.97B est). This marks the end of a four-quarter beat streak, with adjusted gross margin narrowing due to inflation, tariffs, and currency …

Form 8K Kenvue Inc For: 6 August By Investing.com

This article reports that Kenvue Inc. has filed a Form 8K on August 6th. The brief mention indicates a significant event or disclosure made by the company to the SEC. The content itself is very minimal, serving primarily as an announcement of the filing.

Kenvue Reports Second Quarter 2026 Results

Delivered Third Consecutive Quarter of Net and Organic Sales1 Growth Net Sales Increased 3.0%; Organic SalesIncreased 1.6% Diluted EPS Increased 9% to $0.24; Adjusted Diluted EPS1 Increased 7% to $0.31 Results Met or Exceeded the Company's Plans Across Key Metrics SUMMIT, N.J., August 06, …

Kenvue Inc. (NYSE: KVUE) grows Q2 sales 3% and lifts EPS 9%

Kenvue Inc. reported Q2 2026 financial results, showing a 3.0% increase in net sales to $3.96 billion and a 9% rise in diluted earnings per share to $0.24. The company highlighted strong organic sales growth, particularly in Skin Health and Beauty, and announced U.S. …

Kenvue posts Q2 2026: Net sales +3.0%, diluted EPS $0.24, adjusted EPS $0.31

Kenvue (KVUE) reported its Q2 2026 financial results, showing net sales of $3.955 billion, a 3.0% increase year-over-year, and diluted earnings per share of $0.24, with adjusted diluted EPS at $0.31. The company achieved three consecutive quarters of net and organic sales growth across …

Kenvue (KVUE) Lags Q2 Earnings and Revenue Estimates

Kenvue (KVUE) reported Q2 earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.32, though it represents an increase from $0.29 per share a year ago. The company also missed revenue estimates, posting $3.96 billion against an expected $3.99 billion. Despite these …

Kenvue (NYSE: KVUE) Q2 profit climbs as Kimberly-Clark merger advances

Kenvue Inc (KVUE) Earnings Date & Reports & Earnings News

Kenvue earnings in focus as merger with Kimberly-Clark looms

Kenvue Inc. is preparing to report second-quarter earnings, with particular attention on its Skin Health and Beauty division's performance and margin expansion efforts ahead of its $48.7 billion acquisition by Kimberly-Clark. The company will not host a conference call due to the pending merger, …

Cetera Investment Advisers Trims Holdings in Kenvue Inc. $KVUE

Cetera Investment Advisers decreased its stake in Kenvue Inc. (NYSE:KVUE) by 24.7% during the first quarter, now holding 241,189 shares valued at $4.16 million. Despite this, several other institutional investors increased their holdings in Kenvue. The company reported strong earnings, beating analyst estimates, and …

Kenvue (NYSE: KVUE) APAC president converts 16,418.8700 RSUs into common stock

Kenvue's Group President APAC, Anindya Dasgupta, converted 16,418.87 restricted stock units (RSUs) into common shares on July 31, 2026, retaining all acquired shares. After this transaction, Dasgupta directly holds 16,418.87 common shares and 32,831.62 RSUs, which vest in three equal installments. This insider transaction …

Kenvue Inc. stock rises Tuesday, outperforms market

Kenvue Inc. (KVUE) shares increased by 2.84% to $19.55 on Tuesday, ending a three-day losing streak. This performance outpaced the broader market, as the S&P 500 Index rose by 1.79% and the Dow Jones Industrial Average gained 1.71%.

ENvue Medical completes US manufacturing transition

ENvue Medical, Inc. (NASDAQ:FEED) announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States. This strategic move aims to reduce operating expenses, improve cost structure, and consolidate research and development operations in Tel Aviv, Israel. The company …

Kenvue Inc expected to post earnings of 32 cents a share - Earnings Preview

Kenvue Inc is anticipated to report earnings of 32 cents per share. This information is based on an earnings preview. The full article provides more details on this financial projection.

Precision Trading with Kenvue Inc. (KVUE) Risk Zones

The article analyzes Kenvue Inc. (KVUE) and identifies a potential bearish setup with an exceptional 28.0:1 risk-reward ratio, targeting an 8.5% downside. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, and provides multi-timeframe signal analysis with …

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

ENvue Medical has completed the transition of its NanoVibronix manufacturing operations to the United States and consolidated its R&D in Tel Aviv, Israel. This strategic move aims to improve operational efficiency, reduce costs, and streamline supply chain management for the company's acoustic-based therapeutic technologies …

Segall Bryant & Hamill LLC Makes New $3.41 Million Investment in Kenvue Inc. $KVUE

Segall Bryant & Hamill LLC has made a new $3.41 million investment in Kenvue Inc. by purchasing 193,367 shares in the first quarter. Institutional investors now own 97.64% of Kenvue, which analysts generally rate as "Hold" with an average target price of $19.58. The …

PainShield and UroShield Now Made in U.S. by ENvue Medical

ENvue Medical has completed the transition of its NanoVibronix product line manufacturing, including PainShield and UroShield, from Israel to the United States. Concurrently, the company consolidated its research and development operations in Tel Aviv, Israel. These strategic moves aim to improve operational efficiency, reduce …

Kenvue Inc. $KVUE Shares Sold by Glenmede Trust Co. NA

Glenmede Trust Co. NA reduced its stake in Kenvue Inc. (NYSE:KVUE) by 11.7% in the first quarter, selling 53,193 shares. Despite this, institutional investors collectively own 97.64% of the company's stock. Kenvue reported strong Q1 earnings, beating analyst estimates with $0.32 EPS and a …

KVUE|Kenvue Inc|Price:18.995|Chg%:-0.245

This article provides a detailed financial overview of Kenvue Inc (KVUE), including real-time quotes, market trends, key figures, and analyst ratings. It highlights the company's healthy fundamentals, high growth potential, and relatively fair valuation within the Personal & Household Products & Services industry. Despite …